Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan and Spironolactone in COVID-19 ARDS
NCT04643691Phase 2Terminated
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of losartan and spironolactone in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Sequential Organ Failure Assessment Score at 7 days. Started Sep 2020; status: terminated.
02
Drugs
losartanspironolactone
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04643691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643691.